Form 4: Moderna CFO James Mock Executes Stock Transactions Under Pre-Arranged Plan

Moderna's Chief Financial Officer, James Mock, engaged in multiple stock transactions, including the vesting of performance and restricted stock units and a sale to cover tax obligations, as detailed in a recent SEC filing.

Summary

• James Mock, the Chief Financial Officer of Moderna, Inc., executed several transactions involving the company's stock.
• These transactions included the vesting of performance stock units (PSUs) and restricted stock units (RSUs), which converted into common stock on a one-for-one basis.
• On November 27, 2024, 1,326 PSUs and 1,655 RSUs vested, resulting in the acquisition of 3,307 shares of common stock.
• Additionally, on November 29, 2024, 1,420 shares were sold at a price of $42.7891 per share to cover tax withholding obligations related to the vesting of the PSUs and RSUs.
• Following these transactions, Mr. Mock beneficially owns 11,066 shares of common stock.

Sentiment

Score: 6

Explanation: The document reflects routine insider transactions, which are neither particularly positive nor negative. The transactions are part of a pre-arranged plan and do not indicate any significant change in the company's outlook.

Positives

• The vesting of stock units indicates that performance criteria were met, which is a positive sign for the company's performance.
• The transactions were part of a pre-arranged plan, suggesting they were not based on any new material non-public information.

Negatives

• The sale of 1,420 shares, while for tax obligations, could be perceived negatively by some investors as it reduces the CFO's direct holdings.

Risks

• The sale of shares to cover tax obligations could potentially create downward pressure on the stock price, although this is a common practice.
• Changes in the company's performance or stock price could affect the value of future vesting of stock units.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure of insider transactions and is common for publicly traded companies. It provides transparency into the stock ownership of key executives.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the biotechnology sector like Moderna.
• The vesting schedules for stock units are typical for executive compensation packages, with staggered vesting periods to incentivize long-term performance.
• The sale of shares to cover tax obligations is a standard procedure and is not unique to Moderna or its executives. Companies like BioNTech and Pfizer also have similar disclosures.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine insider activity.
• The sale of shares to cover tax obligations is a standard practice and does not significantly affect the company's operations or financial health.

Key Dates

Keywords

Moderna, MRNA, SEC Form 4, James Mock, stock transactions, performance stock units, restricted stock units, insider trading, Rule 10b5-1, vesting, tax withholding